On February 11, 2025 Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, reported to host a virtual R&D update with KOL (Key Opinion Leader) speakers on February 18, 2025 (Press release, Vivoryon Therapeutics, FEB 11, 2025, View Source [SID1234650176]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webcast will include presentations from management and KOLs discussing further analyses and data on varoglutamstat’s observed beneficial effect on kidney function, an update on the Company’s anticipated clinical development plan for varoglutamstat in kidney disease, varoglutamstat’s potential market positioning, and an opportunity for investor and analyst questions.
Featured KOL speakers include:
Tobias B. Huber, MD – Chair of the Center of Internal Medicine and Director of the III. Department of Medicine – University Medical Center Hamburg-Eppendorf (UKE), Germany. Acting as Medical Advisor for clinical study design and certain R&D activities.
Kevin Carroll, PhD – CEO, KJC Statistics. Acting as statistical analysis expert, providing and calculating statistical read-outs and advising on clinical study statistical aspects.
Webcast details
Date: February 18, 2025
Time: 3:00 pm CET / 9:00 am EST
Further details of the event and participation information are available at: View Source
About Varoglutamstat
Varoglutamstat (PQ912) is a proprietary, potent and selective inhibitor of human glutaminyl cyclases QPCT and QPCTL with therapeutic potential in indications including inflammatory and fibrotic diseases, neurodegenerative diseases, cancer and others. Initially advanced development aiming to treat Alzheimer’s disease (AD), varoglutamstat has been investigated in a number of different clinical studies. Based on the known anti-inflammatory and anti-fibrotic activity of varoglutamstat, the protocol for the Phase 2b VIVIAD study in early AD included the investigation of kidney function (measured using eGFR) and measurement of biomarkers of kidney inflammation and fibrosis to explore the role of QPCT/L inhibition on kidney function. eGFR was also analyzed as a prospectively defined safety parameter in the VIVA-MIND Phase 2 study in the U.S.